论文部分内容阅读
为进行康莱特注射液Ⅲ期检验临床抗癌疗效及病理学变化，北京胸部肿瘤结核病医院等单位联合对７５例原发性肺癌病例进行了观察。其中术前用康莱特治疗４５例，未治疗３０例。结果显示，康莱特治疗组有效率达２０％（９／４５），临床未见明显毒副作用。术后病理观察，肿瘤组织坏死面积达２５％以上者占６２２２％（２８／４５），对照组为２６６７％（８／３０），两组差别明显（Ｐ＜００５）。根据癌细胞组织对康莱特治疗反应程度不同分为０级（无反应）、Ⅰ级（轻度）、Ⅱ级（中度）和Ⅲ级（重度）。康莱特组以Ⅰ级和Ⅱ级居多，占９５６％（４３／４５），而对照组以０级和Ⅰ级为主，占８６７％（２６／３０），两组比较差别显著（Ｐ＜００１）。依据临床及病理学观察结果，认为康莱特注射液对治疗原发性肺癌有一定的疗效。
In order to carry out the clinical anti-cancer efficacy and pathological changes of Kanglaite injection phase III test, Beijing Breast Cancer Tuberculosis Hospital and other units jointly observed 75 cases of primary lung cancer. Among them, 45 were treated with Kanglaite before operation and 30 were untreated. The results showed that the Kanglaite treatment group had an effective rate of 20% (9/45), and no obvious toxic side effects were observed in the clinic. Pathological observation revealed that tumor necrosis area of more than 25% accounted for 6222% (28/45), and control group had 2667% (8/30). There was a significant difference between the two groups (P<005). According to the degree of cancer tissue response to Kanglaite treatment is divided into 0 (no response), I (mild), II (moderate) and III (heavy). The Kanglaite group was mostly grade I and grade II, accounting for 95.6% (43/45), while the control group was grade 0 and grade I, accounting for 86.7% (26/30). The difference was significant between the two groups. (P<001). According to clinical and pathological observations, Kanglaite Injection is considered to have a certain effect on the treatment of primary lung cancer.